PMDI / Psychemedics Corporation - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Power of Attorney

EXHIBIT 24 Power of Attorney KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned, being a director or officer, or both, of Psychemedics Corporation, a Delaware corporation (hereinafter called the “Corporation”), does hereby constitute and appoint Brian Hullinger and Daniella Mehalik, with full power to each of them to act alone, as the true and lawful attorneys and agents of the under

Subsidiaries of the Registrant

EXHIBIT 21.1 PSYCHEMEDICS CORPORATION Subsidiaries Psychemedics Corporation wholly-owns the following companies: Name Country of Incorporation 1. Psychemedics International, LLC Delaware, USA 2. Psychemedics Laboratórios Ltda Brazil (owned jointly by Psychemedics Corporation and Psychemedics International, LLC)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-13738 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified

As filed with the Securities and Exchange Commission on March 19, 2025

As filed with the Securities and Exchange Commission on March 19, 2025 Registration No.

As filed with the Securities and Exchange Commission on March 19, 2025

As filed with the Securities and Exchange Commission on March 19, 2025 Registration No.

As filed with the Securities and Exchange Commission on March 19, 2025

As filed with the Securities and Exchange Commission on March 19, 2025 Registration No.

As filed with the Securities and Exchange Commission on March 19, 2025

As filed with the Securities and Exchange Commission on March 19, 2025 Registration No.

As filed with the Securities and Exchange Commission on March 19, 2025

As filed with the Securities and Exchange Commission on March 19, 2025 Registration No.

As filed with the Securities and Exchange Commission on March 19, 2025

As filed with the Securities and Exchange Commission on March 19, 2025 Registration No.

As filed with the Securities and Exchange Commission on March 19, 2025

As filed with the Securities and Exchange Commission on March 19, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-13738 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-13738 PSYCHEMEDICS CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-13738 PSYCHEMEDICS CORPORATION The Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 5

PMD / Psychemedics Corporation / Kamin Peter Activist Investment

SC 13D/A 1 eps11668kamin.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 9)1 Psychemedics Corporation (Name of Issuer) Common Stock, par value $0.005 per share (Title of Class of Securities) 74437520

Stock Repurchase Agreement, by and between Psychemedics Corporation and 3K Limited Partnership, dated December 10, 2024.

Exhibit 99.5 STOCK REPURCHASE AGREEMENT This Stock Repurchase Agreement (this “Agreement”) is entered into as of December 10, 2024 (the “Effective Date”) by and between Psychemedics Corporation, a Delaware corporation (the “Company”), and 3K Limited Partnership, a Delaware limited partnership (the “Selling Stockholder”). The Company and Selling Stockholder are each referred to herein as a “Party”

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) Psychemedics Corporation (Name of the Issuer and Name of Person Filing Statement)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) Psychemedics Corporation (Name of the Issuer and Name of Person Filing Statement) Common Stock, $0.005 par value per share (Title of Class of Securities) 744375304 (CUSIP Number of Class of Securities) Brian Hullinger President and

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 PSYCHEMEDICS CORPORATION (Exact name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commissio

PMD / Psychemedics Corporation / POWELL ANDERSON CAPITAL LP - SC 13G/A Passive Investment

SC 13G/A 1 tm2430450d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Psychemedics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 744375205 (CUSIP Number) December 4, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to

PMD / Psychemedics Corporation / Kamin Peter Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 8)1 Psychemedics Corporation (Name of Issuer) Common Stock, par value $0.005 per share (Title of Class of Securities) 744375205 (CUSIP Number) PETER H. KAM

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 PSYCHEMEDICS CORPORATION (Exact name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission

Certificate of Amendment, filed December 3, 2024, to effect the 5,000-for-1 Forward Stock Split.

Exhibit 3.2 CERTIFICATE OF AMENDMENT OF amended and restated CERTIFICATE OF INCORPORATION OF PSYCHEMEDICS CORPORATION Pursuant to Section 242 of the Delaware General Corporation Law, Psychemedics Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: Article FOURTH of the Amended and Restated Certificate

Certificate of Amendment, filed December 3, 2024, to effect the 1-for-5,000 Reverse Stock Split.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF PSYCHEMEDICS CORPORATION Pursuant to Section 242 of the Delaware General Corporation Law, Psychemedics Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: Article FOURTH of the Amended and Restated Certificate of Incorporation of the Corporation is hereby amende

Psychemedics Corporation Announces Reverse and Forward Stock Split

EXHIBIT 99.1 Psychemedics Corporation Announces Reverse and Forward Stock Split DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) - Psychemedics Corporation (Nasdaq: PMD) (the “Company”), the world’s leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company’s stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company’s Boar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 PSYCHEMEDICS CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

DEFA14A 1 defa14a112524.htm DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as

Psychemedics Corporation Reports Third Quarter 2024 Financial Results

EXHIBIT 99.1 Psychemedics Corporation Reports Third Quarter 2024 Financial Results DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September 30, 2024. The Company’s revenue for three months ended September 30, 2024, was $5.2 million versus

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 or ☐ Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS COR

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commissio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Psychemedics Corporation (Name of the Issuer and Name of Person Filing Statement)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Psychemedics Corporation (Name of the Issuer and Name of Person Filing Statement) Common Stock, $0.005 par value per share (Title of Class of Securities) 744375205 (CUSIP Number of Class of Securities) Brian Hullinger President and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Psychemedics Corporation (Name of the Issuer and Name of Person Filing Statement)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Psychemedics Corporation (Name of the Issuer and Name of Person Filing Statement) Common Stock, $0.005 par value per share (Title of Class of Securities) 744375205 (CUSIP Number of Class of Securities) Brian Hullinger President and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Boston    Los Angeles    New York    San Diego    San Francisco    TORONTO   Washington MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

One Financial Center Boston, MA 02111 617 542 6000 mintz.com October 16, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Officer of Mergers & Acquisitions 100 F Street, N.E. Washington, D.C. 20549 Attention: Brian Soares and David Plattner Re: PSYCHEMEDICS CORP Schedule 13E-3/A filed October 4, 2024 File No. 005-39145 (the “Amendment No. 1 to Schedule 13E-3”) Revi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Psychemedics Corporation (Name of the Issuer and Name of Person Filing Statement)

SC 13E3/A 1 sc13e3a100324.htm SC 13E3/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Psychemedics Corporation (Name of the Issuer and Name of Person Filing Statement) Common Stock, $0.005 par value per share (Title of Class of Securities) 744375205 (CUSIP Number of Class of Se

Boston Los Angeles New York San Diego San Francisco TORONTO Washington MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

One Financial Center Boston, MA 02111 617 542 6000 mintz.com October 4, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Officer of Mergers & Acquisitions 100 F Street, N.E. Washington, D.C. 20549 Attention: Brian Soares and David Plattner Re: PSYCHEMEDICS CORP Schedule 13E-3 filed September 3, 2024 File No. 005-39145 (the “Schedule 13E-3”) Preliminary Proxy Statem

107         Filing Fee Table (previously filed as Exhibit 107 to the Schedule 13E-3 filed on September 3, 2024).

Exhibit 107 Calculation of Filing Fee Tables Schedule 13E-3 (Form Type) Psychemedics Corporation (Name of the Issuer and Name of Person Filing Statement) Table 1 – Transaction Value Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fees to Be Paid $ 2,987,223.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Psychemedics Corporation (Name of the Issuer and Name of Person Filing Statement) C

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Psychemedics Corporation (Name of the Issuer and Name of Person Filing Statement) Common Stock, $0.005 par value per share (Title of Class of Securities) 744375205 (CUSIP Number of Class of Securities) Brian Hullinger President and C

(c)(iii)     Presentation, dated June 5, 2024 of Mirus to the Board of Directors of the Company (previously filed as Exhibit (c)(iii) to the Schedule 13E-3 filed on September 3, 2024).

Exhibit (c)(iii) 1 DRAFT – CONFIDENTIAL PREPARED JULY 2022 FOR: Prepared April 2024 for: Project Northern Lights Presentation prepared for the Transaction Committee of the Board of Directors June 5, 2024 2 DRAFT – CONFIDENTIAL • Mirus has relied upon and assumed the accuracy and completeness of all information that was publicly available or provided to us by the Company, and has not independently verified such information.

(c)(iv)     Presentation, dated April 10, 2024 of Mirus to the Board of Directors of the Company (previously filed as Exhibit (c)(iv) to the Schedule 13E-3 filed on September 3, 2024).

Exhibit (c)(iv) 1 DRAFT – CONFIDENTIAL PREPARED JULY 2022 FOR: Prepared April 2024 for: Project Northern Lights Presentation prepared for the Transaction Committee of the Board of Directors April 10, 2024 2 DRAFT – CONFIDENTIAL 2 • Mirus has relied upon and assumed the accuracy and completeness of all information that was publicly available or provided to us by the Company, and has not independently verified such information.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

(c)(ii)      Presentation, dated August 12, 2024 of Mirus to the Board of Directors of the Company (previously filed as Exhibit (c)(ii) to the Schedule 13E-3 filed on September 3, 2024).

Exhibit (c)(ii) 1 DRAFT – CONFIDENTIAL PREPARED JULY 2022 FOR: Prepared April 2024 for: Project Northern Lights Presentation prepared for the Transaction Committee of the Board of Directors August 12, 2024 2 DRAFT – CONFIDENTIAL • Mirus Securities, Inc.

PMD / Psychemedics Corporation / Kamin Peter Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 7)1 Psychemedics Corporation (Name of Issuer) Common Stock, par value $0.005 per share (Title of Class of Securities) 744375205 (CUSIP Number) PETER H. KAM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 or ☐ Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS CORPORAT

Psychemedics Corporation Reports Second Quarter 2024 Financial Results

EXHIBIT 99.1 Psychemedics Corporation Reports Second Quarter 2024 Financial Results DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the second quarter ending June 30, 2024. The Company’s revenue for three months ended June 30, 2024, was $4.7 million versus $5.5 mi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Psychemedics Corporation (Exact name of registrant as specified in its charter) Delaware 001-13738 58-1701987 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Psychemedics Corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Psychemedics Corporation (Exact name of registrant as specified in its charter) Delaware 001-13738 58-1701987 (State or other jurisdiction of incorporation) (Commissio

(d)           Stock Purchase Agreement, dated August 12, 2024, by and among the Company, 3K Limited Partnership, Peter H. Kamin, the Peter H. Kamin Revocable Trust dated February 2003, the Peter H. Kamin Childrens Trust dated March 1997, the Peter H. Kamin GST Trust and the Peter H. Kamin Family Foundation (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 12, 2024 and incorporated herein by reference).

Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”), dated as of August 12, 2024 (the “Effective Date”), is made by and among Psychemedics Corporation, a Delaware corporation (the “Company”), 3K Limited Partnership, a Delaware limited partnership (“3K”), Peter H. Kamin, a natural person in his individual capacity (“Mr. Kamin”), the Peter H. Kamin Revocable Trust

Psychemedics Corporation’s Board of Directors Approves Plan to Terminate Registration of Its Common Stock

EXHIBIT 99.1 Psychemedics Corporation’s Board of Directors Approves Plan to Terminate Registration of Its Common Stock DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) - Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) today announced that a Transaction Committee (the “Transaction Committee”) of the Board of Directors of the Company (the “Board”) comprised of independent directors has

Press Release, dated August 12, 2024.

EXHIBIT 99.1 Psychemedics Corporation’s Board of Directors Approves Plan to Terminate Registration of Its Common Stock DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) - Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) today announced that a Transaction Committee (the “Transaction Committee”) of the Board of Directors of the Company (the “Board”) comprised of independent directors has

Stock Purchase Agreement, by and among Psychemedics Corporation, 3K Limited Partnership, Peter H. Kamin, the Peter H. Kamin Revocable Trust dated February 2003, the Peter H. Kamin Childrens Trust dated March 1997, the Peter H. Kamin GST Trust and the Peter H. Kamin Family Foundation, dated August 12, 2024.

Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”), dated as of August 12, 2024 (the “Effective Date”), is made by and among Psychemedics Corporation, a Delaware corporation (the “Company”), 3K Limited Partnership, a Delaware limited partnership (“3K”), Peter H. Kamin, a natural person in his individual capacity (“Mr. Kamin”), the Peter H. Kamin Revocable Trust

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 PSYCHEMEDICS CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R.S.

Letter from BDO USA, P.C. to the Securities and Exchange Commission dated June 11, 2024.

[Exhibit 16] June 11, 2024 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on June 6, 2024, to be filed by our former client, Psychemedics Corporation. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, /s/

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 PSYCHEMEDICS CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R.S.

Psychemedics Corporation Reports First Quarter 2024 Financial Results

EXHIBIT 99.1 Psychemedics Corporation Reports First Quarter 2024 Financial Results DALLAS, May 14, 2024 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024. The Company’s revenue for the quarter ended March 31, 2024, was $5.4 million versus $5.9 milli

Ninth Amendment to Lease dated March 29, 2024, with Mitchell H. Hersch, et.al. California — Supersedes the Eighth amendment in its entirety

EX-10.1 2 ex666408.htm EXHIBIT 10.1 Exhibit 10.1 NINTH AMENDMENT TO LEASE This NINTH AMENDMENT TO LEASE (the "Amendment") is made and entered into as of the 29 day of March 2024, by and between UPLANDER LLC(“Lessor") and PSYCHEMEDICS CORPORATION, a Delaware corporation ("Lessee"), with respect to that Standard Industrial Lease dated October 6, 1992, and amended January 1, 1993, December 16, 1994,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS CORPORA

Form of Time Based Stock Option Agreement with Employees under 2006 Incentive Plan

Exhibit 10.17 INCENTIVE STOCK OPTION AGREEMENT (TIME-BASED OPTION) INCENTIVE STOCK OPTION AGREEMENT (the “Option Agreement”) made this day of , 20 between PSYCHEMEDICS CORPORATION, a Delaware corporation (hereinafter called the “Corporation”), and, an employee of the Corporation (hereinafter called the “Optionee”). The Corporation desires, by affording the Optionee an opportunity to purchase share

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 PSYCHEMEDICS CORPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission F

Subsidiaries of the Registrant

EXHIBIT 21.1 PSYCHEMEDICS CORPORATION Subsidiaries Psychemedics Corporation wholly-owns the following companies: Name Country of Incorporation 1. Psychemedics International, LLC Delaware, USA 2. Psychemedics Laboratórios Ltda Brazil (owned jointly by Psychemedics Corporation and Psychemedics International, LLC)

Psychemedics Corporation Reports 2023 Financial Results

EXHIBIT 99.1 Psychemedics Corporation Reports 2023 Financial Results DALLAS, March 28, 2024 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. “2023 proved to be another challenging year due to the negative impact of major economic forces. The labor short

Form of Performance-based Stock Option Agreement with Employees under 2006 Incentive Plan

Exhibit 10.18 NON QUALIFIED STOCK OPTION AGREEMENT (PERFORMANCE-BASED INDUCEMENT OPTION) NON QUALIFIED STOCK OPTION AGREEMENT (the “Option Agreement”) made this day of , 20 between PSYCHEMEDICS CORPORATION, a Delaware corporation (hereinafter called the “Corporation”), and , an employee of the Corporation (hereinafter called the “Optionee”). The Corporation desires, by affording the Optionee an op

Clawback Policy

EXHIBIT 97 PSYCHEMEDICS CORPORATION CLAWBACK POLICY The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Psychemedics Corporation (the “Company”) believes that it is appropriate for the Company to adopt this Clawback Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date.

Employment Offer letter dated September 1, 2023 with Shannon Shoemaker

Exhibit 10.16 September 1, 2023 Shannon Shoemaker 6441 Buckner St. Canal Winchester, OH 43110 Re: Offer of Employment Dear Shannon: On behalf of Psychemedics Corporation (“Psychemedics” or the “Company”), I am pleased to offer you employment with the Company. This offer letter agreement (the “Agreement”) provides the terms and conditions of your employment with the Company. 1. Position. Your start

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-13738 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified

Power of Attorney

EXHIBIT 24 Power of Attorney KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned, being a director or officer, or both, of Psychemedics Corporation, a Delaware corporation (hereinafter called the “Corporation”), does hereby constitute and appoint Brian Hullinger and Daniella Mehalik, with full power to each of them to act alone, as the true and lawful attorneys and agents of the under

PMD / Psychemedics Corporation / KUBACKI RAYMOND C JR - SC 13G/A Passive Investment

SC 13G/A 1 sc13ga020224.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Psychemedics Corporation (Name of Issuer) Common Stock - $.005 Par Value 744375205 (CUSIP Number) December 31, 2023 Date of Event which requires filing of this statement Check the appropriate box to designate the rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 PSYCHEMEDICS COR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission

PMD / Psychemedics Corp. / POWELL ANDERSON CAPITAL LP - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Psychemedics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 744375205 (CUSIP Number) December 4, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ¨ Rule 13d-1(b) x Rule 13d-1(c) ¨ Rule 13

Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

EXHIBIT 99.1 Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 PSYCHEMEDICS CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commissio

Employment Agreement with Daniella Mehalik dated November 27, 2023

Exhibit 10.1 November 27, 2023 Daniella Mehalik Pittsburgh, PA Dear Daniella, On behalf of Psychemedics Corporation (“Psychemedics” or the “Company”), I am pleased to extend a formal offer of employment to you with the Company. This offer letter agreement (the “Agreement”) provides the terms and conditions of your employment with the Company. Your tentative start date is November 27, 2023. 1. Posi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS COR

Psychemedics Corporation Reports Third Quarter 2023 Financial Results

EXHIBIT 99.1 Psychemedics Corporation Reports Third Quarter 2023 Financial Results ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company’s revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commissi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission

Power of Attorney.

Exhibit 24.1 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned, being a director, officer or both, of PSYCHEMEDICS CORPORATION, a Delaware corporation (hereinafter the “Corporation”), does hereby severally constitute and appoint, BRIAN HULLINGER and PATRICK J. KINNEY, JR., with full power to each of them to act alone, as the true and lawful attorneys and agents of the

Filing fee table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Psychemedics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock $0.

Securities and Exchange Commission Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PSYCHEMEDICS CORPORATION (Exact name of issuer as specified in its charter)

Registration No. Securities and Exchange Commission Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PSYCHEMEDICS CORPORATION (Exact name of issuer as specified in its charter) DELAWARE 58-1701987 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 289 Great Road, Acton, Massachusetts, 01720 (Address of principa

Form of Performance-based Inducement Stock Option Agreement with Chief Executive Officer – (incorporated by reference from Registrant’s Current Report on Form 8-K filed on August 21, 2023)

Exhibit 10.2 NON QUALIFIED STOCK OPTION AGREEMENT (PERFORMANCE-BASED INDUCEMENT GRANT) NON QUALIFIED STOCK OPTION AGREEMENT (the “Option Agreement”) made this 17th day of August, 2023 between PSYCHEMEDICS CORPORATION, a Delaware corporation (hereinafter called the “Corporation”), and Brian Hullinger, an employee or independent contractor of the Corporation or one or more of its subsidiaries (herei

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission

Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EXHIBIT 99.1 Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ACTON, Mass., Aug. 18, 2023 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering into empl

Form of Time Based Inducement Stock Option Agreement with Chief Executive Officer – (incorporated by reference from Registrant’s Current Report on Form 8-K filed on August 21, 2023)

Exhibit 10.1 NON QUALIFIED STOCK OPTION AGREEMENT (TIME-BASED INDUCEMENT GRANT) NON QUALIFIED STOCK OPTION AGREEMENT (the “Option Agreement”) made this 17th day of August, 2023 between PSYCHEMEDICS CORPORATION, a Delaware corporation (hereinafter called the “Corporation”), and Brian Hullinger, an employee or independent contractor of the Corporation or one or more of its subsidiaries (hereinafter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS CORPORAT

Psychemedics Corporation Reports Second Quarter 2023 Financial Results

EXHIBIT 99.1 Psychemedics Corporation Reports Second Quarter 2023 Financial Results ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company’s revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission

Confidential Settlement Agreement and Release, dated July 17, 2023 by and between Transportation Insight, LLC and Psychemedics Corporation

Exhibit 10.1 CONFIDENTIAL SETTLEMENT AGREEMENT AND RELEASE THIS CONFIDENTIAL SETTLEMENT AGREEMENT AND RELEASE (hereinafter referred to as the “Agreement”) is made and entered into, effective July 17, 2023, by and between Transportation Insight, LLC (“TI”) and Psychemedics Corporation (“PMD”)(TI and PMD are sometimes jointly referred to as the “Parties”, and individually referred to as a “Party”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 PSYCHEMEDICS CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Def

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2023 PSYCHEMEDICS CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2023 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R.S.

Employment Agreement with Brian Hullinger

Exhibit 10.1 July 12, 2023 Brian Hullinger 8129 Grand Shores Drive Sarasota, FL 34240 Re: Offer of Employment Dear Brian: On behalf of Psychemedics Corporation (“Psychemedics” or the “Company”), I am pleased to offer you employment with the Company. This offer letter agreement (the “Agreement”) provides the terms and conditions of your employment with the Company. 1. Position. Your start date of e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS CORPORA

Psychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash Dividend

EXHIBIT 99.1 Psychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash Dividend ACTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2023, and the declaration of a cash dividend of $0.07 per share to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 PSYCHEMEDICS CORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 -12-31FY2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-13738 PSYCHEMEDICS CORPORATION (Exact N

Change in Control Severance agreement with Charles Doucot dated March 21, 2023 (2)

Exhibit 10.11 March 21, 2023 CONFIDENTIAL Charles Doucot c/o Psychemedics Corporation 289 Great Road Acton, MA 01720 Dear Charlie: This letter sets forth the agreements we have made regarding your employment with Psychemedics Corporation (the “Company”). Definitions not defined in the text below shall have the meanings set forth in Paragraph 14. 1. If at any time after the effective date hereof an

Change in control severance agreement with Ray Kubacki dated March 21, 2023

Exhibit 10.9 March 21, 2023 CONFIDENTIAL Mr. Raymond C. Kubacki c/o Psychemedics Corporation 289 Great Road Suite 200 Acton, MA 01720 Dear Ray: This letter sets forth the agreements we have made regarding your employment with Psychemedics Corporation (the “Company”). Definitions not defined in the text below shall have the meanings set forth in Paragraph 14. 1. If at any time after the effective d

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-13738 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified

Power of Attorney

EXHIBIT 24 Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned, being a director or officer, or both, of Psychemedics Corporation, a Delaware corporation (hereinafter called the “Corporation”), does hereby constitute and appoint Raymond C.

Eighth Amendment to Lease dated March 20, 2022, with Mitchell H. Hersch, et.al. California — Supersedes the Seventh amendment in its entirety (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022)

Exhibit 10.2.8 EIGHTH AMENDMENT TO LEASE This EIGHTH AMENDMENT TO LEASE (the "Amendment") is made and entered into as of the 20th day of March 2022, by and between UPLANDER LLC(“Lessor") and PSYCHEMEDICS CORPORATION, a Delaware corporation ("Lessee"), with respect to that Standard Industrial Lease dated October 6, 1992, and amended January 1, 1993, December 16, 1994, December 31, 1997, May 24, 200

Form of Indemnification Agreement with Directors and Executive Officers of the Company*

Exhibit 10.14 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made as of November 12, 2021 by and between PSYCHEMEDICS CORPORATION, a Delaware corporation (the “Company”), and [●] (the “Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, hig

Subsidiaries of the Registrant

EXHIBIT 21.1 PSYCHEMEDICS CORPORATION Subsidiaries Psychemedics Corporation wholly-owns the following companies: Name Country of Incorporation 1. Psychemedics International, LLC Delaware, USA 2. Psychemedics Laboratórios Ltda Brazil (owned jointly by Psychemedics Corporation and Psychemedics International, LLC)

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission F

Psychemedics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Declares Quarterly Cash Dividend

EXHIBIT 99.1 Psychemedics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Declares Quarterly Cash Dividend ACTON, Mass., March 21, 2023 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced today fourth quarter and full year financial results for the period ended December 31, 2022. The Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 PSYCHEMEDICS CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.

PMD / Psychemedics Corp. / KUBACKI RAYMOND C JR - FORM SC 13G/A Passive Investment

SC 13G/A 1 sc13ga021423.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Psychemedics Corporation (Name of Issuer) Common Stock - $.005 Par Value 744375205 (CUSIP Number) December 31, 2022 Date of Event which requires filing of this statement Check the appropriate box to designate the

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 or ? Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS COR

Psychemedics Corporation Reports Third Quarter 2022 Financial Results and Declares Quarterly Cash Dividend

EXHIBIT 99.1 Psychemedics Corporation Reports Third Quarter 2022 Financial Results and Declares Quarterly Cash Dividend ACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), the world?s largest provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2022. The Company also announced a cash quarterly di

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 or ? Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS CORPORAT

Psychemedics Corporation Reports Second Quarter 2022 Financial Results and Declares Quarterly Cash Dividend

EXHIBIT 99.1 Psychemedics Corporation Reports Second Quarter 2022 Financial Results and Declares Quarterly Cash Dividend ACTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), the world?s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2022. The Company also announced a quarterly dividend o

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission F

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ? ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def

PMD / Psychemedics Corp. / Kamin Peter Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 6)1 Psychemedics Corporation (Name of Issuer) Common Stock, par value $0.005 per share (Title of Class of Securities) 744375205 (CUSIP Number) PETER H. KAM

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission Fil

Psychemedics Announces Two New Director Nominees for its 2022 Annual Meeting of Stockholders and Director Walter S. Tomenson, Jr.’s Retirement after More than 20 Years of Dedicated Service

EXHIBIT 99.1 Psychemedics Announces Two New Director Nominees for its 2022 Annual Meeting of Stockholders and Director Walter S. Tomenson, Jr.?s Retirement after More than 20 Years of Dedicated Service ACTON, Mass., June 09, 2022 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD) announced today that it will be nominating Peter H. Kamin and Darius G. Nevin to serve as new members of its Boa

Cooperation Agreement, dated June 9, 2022, by and among the Company, 3K Limited Partnership, Peter H. Kamin Revocable Trust Dated February 2003, and Peter H. Kamin Childrens Trust Dated March 1977.

Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this ?Agreement?) is made and entered into as of June 9, 2022 by and among Psychemedics Corporation (the ?Company?) and the entities and natural persons set forth in the signature pages hereto (collectively, ?Kamin?) (each of the Company and Kamin, a ?Party? to this Agreement, and collectively, the ?Parties?). RECITALS WHEREAS, the Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 or ? Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS CORPORA

PETER H. KAMIN 2720 Donald Ross Road, Unit #311 Palm Beach Gardens, Florida 33410

Exhibit 99.2 PETER H. KAMIN 2720 Donald Ross Road, Unit #311 Palm Beach Gardens, Florida 33410 May [ ], 2022 [Nominee] [Adress] Re: Psychemedics Corporation Dear [Nominee]: Thank you for agreeing to serve as a nominee for election to the Board of Directors of Psychemedics Corporation (the “Company”) in connection with the proxy solicitation that Peter H. Kamin and his affiliates (collectively, the

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission Fil

PMD / Psychemedics Corp. / Kamin Peter - AMENDMENT NO. 5 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 5)1 Psychemedics Corp (Name of Issuer) Common Stock, par value $0.005 per share (Title of Class of Securities) 744375205 (CUSIP Number) PETER H. KAMIN 2720

POWER OF ATTORNEY

Exhibit 99.3 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Peter H. Kamin the undersigned’s true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned’s beneficial ownership of, or participation in a group with respect to, securities of Psychemedics Corporation., a Delaware corporation (the “Company”), dir

JOINT FILING AND SOLICITATION AGREEMENT

Exhibit 99.1 JOINT FILING AND SOLICITATION AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Psychemedics Corporation, a Delaware corporation (the ?Company?); WHEREAS, 3K Limited Partnership, the Peter H. Kamin Revocable Trust dated February 2003, the Peter H. Kamin Childrens Trust dated March 1997, Peter H. Kamin (together, ?3K?), G3 Investment Holdings, LLC

Psychemedics Corporation Reports First Quarter 2022 Financial Results and Declares Increased Cash Dividend

EXHIBIT 99.1 Psychemedics Corporation Reports First Quarter 2022 Financial Results and Declares Increased Cash Dividend ACTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), the world?s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2022, and the declaration of a cash dividend of $0.07 per

PMD / Psychemedics Corp. / Kamin Peter - AMENDMENT NO. 4 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 4)1 Psychemedics Corp (Name of Issuer) Common Stock, par value $0.005 per share (Title of Class of Securities) 744375205 (CUSIP Number) PETER H. KAMIN 2720

Power of Attorney

EXHIBIT 24 Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned, being a director or officer, or both, of Psychemedics Corporation, a Delaware corporation (hereinafter called the ?Corporation?), does hereby constitute and appoint Raymond C.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-13738 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified

Subsidiaries of the Registrant

EXHIBIT 21.1 PSYCHEMEDICS CORPORATION Subsidiaries Psychemedics Corporation wholly-owns the following companies: Name Country of Incorporation 1. Psychemedics International, LLC Delaware, USA 2. Psychemedics Laborat?rios Ltda Brazil (owned jointly by Psychemedics Corporation and Psychemedics International, LLC) 59

Form of Indemnification Agreement with Directors and Executive Officers of the Company*

EXHIBIT 10.15 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (?Agreement?) is made as of November 12, 2021 by and between PSYCHEMEDICS CORPORATION, a Delaware corporation (the ?Company?), and [?] (the ?Indemnitee?). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, hig

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission F

Psychemedics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results

EXHIBIT 99.1 Psychemedics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results ACTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ: PMD), the world?s largest provider of hair testing for drugs of abuse, announced today fourth quarter and full year financial results for the period ended December 31, 2021. The Company?s revenue for the year ended Decem

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2022 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission F

Psychemedics Corporation Welcomes Drew Reynolds to Its Board of Directors and Announces the Retirement of Harry Connick From His Director Role

EXHIBIT 99.1 Psychemedics Corporation Welcomes Drew Reynolds to Its Board of Directors and Announces the Retirement of Harry Connick From His Director Role ACTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD), the world?s largest provider of hair testing for drugs of abuse, is pleased to welcome Andrew ?Drew? M. Reynolds to the Psychemedics Board of Directors effec

1 0 - March - 2022 Safe Harbor Statement This presentation contains forward - looking information that involves risks and uncertainties, including statements about the Company’s prospects, the Company’s financial performance, targets, goals, and metr

Exhibit 99.1 1 0 - March - 2022 Safe Harbor Statement This presentation contains forward - looking information that involves risks and uncertainties, including statements about the Company?s prospects, the Company?s financial performance, targets, goals, and metrics, participation in multiple ma rke ts, its technology and research and development efforts, the benefits of the Company?s business mod

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R.S

PMD / Psychemedics Corp. / CRAWFORD INVESTMENT COUNSEL INC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* Psychemedics Corporation (Name of Issuer) Common stock, $0.005 par value (Title of Class of Securities) 744375205 (CUSIP Number) Casey K. D

PMD / Psychemedics Corp. / KUBACKI RAYMOND C JR - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Psychemedics Corporation. (Name of Issuer) Common Stock - $.005 Par Value 744375205 (CUSIP Number) December 31, 2021 Date of Event which requires filing of this statement Check the appropriate box to designate the rule pursuant to which this schedule is

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission

PMD / Psychemedics Corp. / Kamin Peter - AMENDMENT NO. 3 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 3)1 Psychemedics Corp (Name of Issuer) Common Stock, par value $0.005 per share (Title of Class of Securities) 744375205 (CUSIP Number) PETER H. KAMIN 2720

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission

Psychemedics Corporation Declares Cash Dividend

EXHIBIT 99.1 Psychemedics Corporation Declares Cash Dividend ACTON, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD), the world?s largest provider of hair testing for drugs of abuse, today announced that it has declared a cash dividend of $0.05 per share to be paid on December 30th, 2021 to shareholders of record as of December 20th, 2021. As the record shows, the Comp

Change in control severance with Andrew Limbek dated August 10, 2021

Exhibit 10.1 August 10, 2021 CONFIDENTIAL Andrew Limbek c/o Psychemedics Corporation 289 Great Road Acton, MA 01720 Dear Andrew: This letter sets forth the agreements we have made regarding your employment with Psychemedics Corporation (the ?Company?). Definitions not defined in the text below shall have the meanings set forth in Paragraph 15. 1. If at any time after September 1, 2021 and prior to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 or ? Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS COR

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 PSYCHEMEDICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commissio

Psychemedics Corporation Reports Stronger Revenue, Operating Profit and Earnings Growth in Third Quarter 2021

EXHIBIT 99.1 Psychemedics Corporation Reports Stronger Revenue, Operating Profit and Earnings Growth in Third Quarter 2021 ACTON, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD), the world?s largest provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2021. The Company?s revenue for the quarter ended

Peter H. Kamin 2720 Donald Ross Road, Unit #311 Palm Beach Gardens, FL 33410

Exhibit 99.1 Peter H. Kamin 2720 Donald Ross Road, Unit #311 Palm Beach Gardens, FL 33410 September 23, 2021 BY EMAIL Psychemedics Corporation 289 Great Road Acton, MA 01720 Attention: Board of Directors Ladies and Gentlemen: As you are aware, I am one of the largest stockholders of Psychemedics Corporation (“Psychemedics” or the “Company”), owning approximately 8.4% of the outstanding shares of c

PMD / Psychemedics Corp. / Kamin Peter - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 2)1 Psychemedics Corp (Name of Issuer) Common Stock, par value $0.005 per share (Title of Class of Securities) 744375205 (CUSIP Number) PETER H. KAMIN 2720

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2021 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commissi

PMD / Psychemedics Corp. / Kamin Peter - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Psychemedics Corp (Name of Issuer) Common Stock, par value $0.005 per share (Title of Class of Securities) 744375205 (CUSIP Number) PETER H. KAMIN 2720

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 or ? Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS CORPORAT

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 10, 2021 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission File

Psychemedics Corporation Reports Stronger Second Quarter 2021 Financial Results

EXHIBIT 99.1 Psychemedics Corporation Reports Stronger Second Quarter 2021 Financial Results ACTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD), the world?s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2021. The Company?s revenue for the quarter ended June 30, 2021, was $6.1 million ve

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2021 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R.S.

Securities and Exchange Commission Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PSYCHEMEDICS CORPORATION (Exact name of issuer as specified in its charter)

Registration No. Securities and Exchange Commission Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PSYCHEMEDICS CORPORATION (Exact name of issuer as specified in its charter) DELAWARE 58-1701987 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 289 Great Road, Acton, Massachusetts 01720 (Address of principal

Power of Attorney

Exhibit 24.1 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned, being a director, officer or both, of PSYCHEMEDICS CORPORATION, a Delaware corporation (hereinafter the ?Corporation?), does hereby constitute and appoint, RAYMOND C. KUBACKI and PATRICK J. KINNEY, JR., with full power to each of them to act alone, as the true and lawful attorneys and agents of the undersi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R.S.

10.1 Amended and Restated 2006 Incentive Plan

Exhibit 10.1 PSYCHEMEDICS CORPORATION 2006 INCENTIVE PLAN As Amended and Restated on March 23, 2021 1. Establishment, Purpose; Duration; Definitions A. Establishment of the Plan. This 2006 Incentive Plan (the ?Plan?) was first adopted by the Board of directors of Psychemedics Corporation, a Delaware corporation (hereinafter referred to as the ?Company?), on March 22, 2006 (the ?Effective Date?). T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 or ? Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS CORPORA

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 10, 2021 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Psychemedics Corporation Reports First Quarter 2021 Financial Results

EXHIBIT 99.1 Psychemedics Corporation Reports First Quarter 2021 Financial Results ACTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD), the world?s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2021. The Company?s revenue for the quarter ended March 31, 2021 was $5.7 million versus $7.5 m

Annual Report - FORM 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-13738 PSYCHEMEDICS CORPORATION (Exact Name of Regist

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Subsidiaries of the Registrant

EXHIBIT 21.1 PSYCHEMEDICS CORPORATION Subsidiaries Psychemedics Corporation wholly-owns the following companies: Name Country of Incorporation 1. Psychemedics International, LLC Delaware, USA 2. Psychemedics Laborat?rios Ltda Brazil (owned jointly by Psychemedics Corporation and Psychemedics International, LLC)

Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-13738 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified

Power of Attorney

EXHIBIT 24 Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned, being a director or officer, or both, of Psychemedics Corporation, a Delaware corporation (hereinafter called the ?Corporation?), does hereby constitute and appoint Raymond C.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 19, 2021 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission File

Psychemedics Corporation Reports Fourth Quarter and Full Year 2020 Financial Results

EXHIBIT 99.1 Psychemedics Corporation Reports Fourth Quarter and Full Year 2020 Financial Results ACTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD), the world?s largest provider of hair testing for drugs of abuse, today announced fourth quarter and full year financial results for the period ended December 31, 2020. The Company's revenue for the year ended Decemb

Conditional Waiver dated March 19, 2021, and Amendment Number 002 dated March 23, 2021 to Master Loan and Security Agreement Amendment dated March 19, 2014 between Banc of America Leasing & Capital, LLC and Psychemedics Corporation LLC — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on March 23, 2021)

EXHIBIT 10.1 March 15, 2021 Psychemedics Corporation 289 Great Road Acton, MA 01720 Attn: Andrew Limbek Re: Conditional Waiver Dear Mr. Limbek Reference is made to that certain Master Loan and Security Agreement No. 26928-70000 dated as of March 19, 2014 (as amended, modified or supplemented from time to time, the ?Master Loan Agreement?) between Banc of America Leasing & Capital, LLC (?BALC?) and

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 16, 2021 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission File

Robyn C. Davis Joins Psychemedics Board of Directors

EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Raymond C. Kubacki, Chairman, President and CEO Phone: (978) 206-8220 Robyn C. Davis Joins Psychemedics Board of Directors Acton, Massachusetts, March 17, 2021 – Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporation effe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDME

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* Psychemedics Corporation (Name of Issuer) Common stock, $0.005 par value (Title of Class of Securities) 744375205 (CUSIP Number) Casey K. D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Psychemedics Corporation. (Name of Issuer) Common Stock - $.005 Par Value (CUSIP Number) December 31, 2020 Date of Event wh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Psychemedics Corporation. (Name of Issuer) Common Stock - $.005 Par Value 744375205 (CUSIP Number) December 31, 2020 Date of Event which requires filing of this statement Check the appropriate box to designate the rule pursuant to which this schedule is filed: [ ] Rule 13d

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. __)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Psychemedics Corp (Name of Issuer) Common Stock (Title of Class of Securities) 744375205 (CUSIP Number) Peter H. Kamin 2720 Donald Ross Road, #311 Palm Beach Gardens, FL 33410 (Name, Address and Telephone Number of Person Authorized to Receive Notices and

- FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 or ☐ Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS COR

Psychemedics Announces Third Quarter Results

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Psychemedics Announces Third Quarter Results ACTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2020. The Company’s revenue for the quarter ended September 30, 2020 was $5.2 million versus $9.9 million for the quarter ended September 3

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 9, 2020 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission Fil

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R

Conditional Waiver and Amendment No 1. To Master Loan and Security Agreement dated November 4, 2020, with Banc of America Leasing & Capital, LLC — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on November 9, 2020)

EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 November 04, 2020 Psychemedics Corporation 125 Nagog Park, Ste 200 Acton, MA 01720 Attn: Neil Lerner Re: Conditional Waiver Dear Mr. Lerner Reference is made to that certain Master Loan and Security Agreement No. 26928-70000 dated as of March 19, 2014 (as amended, modified or supplemented from time to time, the “Master Loan Agreement”) between Banc of

Amendment dated September 3, 2020 to Change in Control Severance Agreement between Psychemedics Corporation and Charles Doucot (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on September 10, 2020)

EX-10.2 3 exh102.htm EXHIBIT 10.2 Exhibit 10.2 September 3, 2020 Mr. Charles Doucot c/o Psychemedics Corporation 289 Great Road Suite 200 Acton, MA 01720 Dear Charlie: This letter sets forth an amendment to the letter agreement (the “Letter Agreement”) between you and Psychemedics Corporation (the “Company”) dated May 2, 2018. For good and valuable consideration, the receipt and sufficiency of whi

- FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2020 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.

Amendment dated September 3, 2020 to Change in Control Severance Agreement between Psychemedics Corporation and Michael I. Schaffer

EX-10.3 4 exh103.htm EXHIBIT 10.3 Exhibit 10.3 September 3, 2020 Michael I. Schaffer, Ph.D. c/o Psychemedics Corporation 5832 Uplander Way Culver City, CA 90230-6608 Dear Mike: This letter sets forth an amendment to the letter agreement (the “Letter Agreement”) between you and Psychemedics Corporation (the “Company”) dated February 20, 2018. For good and valuable consideration, the receipt and suf

Amendment dated September 3, 2020 to Change in Control Severance Agreement between Psychemedics Corporation and Raymond C. Kubacki

Exhibit 10.1 September 3, 2020 Mr. Raymond C. Kubacki, Jr. c/o Psychemedics Corporation 289 Great Road Suite 200 Acton, MA 01720 Dear Ray: This letter sets forth an amendment to the letter agreement (the “Letter Agreement”) between you and Psychemedics Corporation (the “Company”) dated February 20, 2018. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowled

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 or [ x] Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS COR

Psychemedics Announces Second Quarter Results

EXHIBIT 99.1 Psychemedics Announces Second Quarter Results ACTON, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2020. The Company’s revenue for the quarter ended June 30, 2020 was $3.3 million versus $9.3 million for the quarter ended June 30, 2019, a decrease of 64%. Net loss for the qua

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 12, 2020 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission File

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R.S.

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 or [ ] Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS COR

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 13, 2020 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Psychemedics Announces First Quarter Results

EXHIBIT 99.1 Psychemedics Announces First Quarter Results ACTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD) today announced first quarter financial results for the period ended March 31, 2020. The Company’s revenue for the quarter ended March 31, 2020 was $7.5 million versus $9.8 million for the quarter ended March 31, 2019, a decrease of 23%. Net loss for the qua

Promissory Note dated May 1, 2020 by Psychemedics Corporation payable to the order of Bank of America, NA.

EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 Promissory Note Date Loan Amount Interest Rate after Deferment Period Deferment Period May 01, 2020 $2,181,157.00 1.00% fixed per annum 6 months This Promissory Note (“Note”) sets forth and confirms the terms and conditions of a term loan to Psychemedics Corporation (whether one or more than one, “Borrower”) from Bank of America, NA, a national bankin

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2020 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R.S. E

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

- DEFA14A

DEFA14A 1 defa14a042820.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as pe

PMD / Psychemedics Corp. DEF 14A - - DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Description of Securities (2)

Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Psychemedics Corporation has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our Common Stock. Description of Common Stock The following description of our Common Stock is a summary and does not

PMD / Psychemedics Corp. 10-K/A - Annual Report - FORM 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-13738 PSYCHEMEDICS CORPORATION (Exact Name of Regist

PMD / Psychemedics Corp. 10-K - Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-13738 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified

Second Amendment dated December 26, 2018 to Lease dated March 12, 2014 with Bristol-Culver Associates, LLC and Mountain Organic Farms, LLC with respect to 6100 Bristol parkway premises in Culver City, CA

EX-10.13.1 2 exh10131.htm EXHIBIT 10.13.1 EXHIBIT 10.13.1

Power of Attorney

EXHIBIT 24 Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned, being a director or officer, or both, of Psychemedics Corporation, a Delaware corporation (hereinafter called the “Corporation”), does hereby constitute and appoint Raymond C.

Subsidiaries of the Registrant

EXHIBIT 21.1 PSYCHEMEDICS CORPORATION Subsidiaries Psychemedics Corporation wholly-owns the following companies: Name Country of Incorporation 1. Psychemedics International, LLC Delaware, USA 2. Psychemedics Laboratórios Ltda Brazil (owned jointly by Psychemedics Corporation and Psychemedics International, LLC)

Letter Agreement dated December 3, 2019 with Banc of America Leasing and Capital, LLC, together with Equipment Security Note dated December 4, 2019 — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019)

EXHIBIT 10.14.3 3400 Pawtucket Avenue Riverside, RI 02915 December 2, 2019 Psychemedics Corporation 289 Great Road, Ste 200 Acton, MA 01720 Attn: Neil Lemer Dear Mr. Lemer: Banc of America Leasing & Capital, LLC (“BALC”) is pleased to confirm its willingness to proceed with the transaction with Psychemedics Corporation (“Debtor”) as set forth and subject to the following: DOCUMENTATION: Debtor sha

PMD / Psychemedics Corp. / CRAWFORD INVESTMENT COUNSEL INC Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* Psychemedics Corporation (Name of Issuer) Common stock, $0.005 par value (Title of Class of Securities) 744375205 (CUSIP Number) December 31, 2019 (Date

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 11, 2020 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission Fi

Psychemedics Corporation Announces 4th Quarter and Year-End Results Declares 94th Consecutive Quarterly Dividend

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Psychemedics Corporation Announces 4th Quarter and Year-End Results Declares 94th Consecutive Quarterly Dividend ACTON, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2019. The Company also announced a quarterly dividend of $

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2020 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R

PMD / Psychemedics Corp. / DEPRINCE RACE & ZOLLO INC - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2019 PSYCHEMEDICS CORPORATION (exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-13738 58-1701987 (Commission

PMD / Psychemedics Corp. 10-Q - Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 or [ ] Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS

Lease dated July 29, 2019 with Culver City/Hannum, LLC with respect to 5750 Hannum premises in Culver City, CA — (Incorporated by reference from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019)

Exhibit 10.13.2

Psychemedics Announces Third Quarter Results and Declares 93rd Consecutive Quarterly Dividend

EXHIBIT 99.1 Psychemedics Announces Third Quarter Results and Declares 93rd Consecutive Quarterly Dividend ACTON, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2019. The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of November 5,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 22, 2019 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission Fil

Psychemedics Corporation Announces New Brazilian Distribution Agreement

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Psychemedics Corporation Announces New Brazilian Distribution Agreement ACTON, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) - Psychemedics Corporation (Nasdaq:PMD) announced today that it has entered into a new distribution agreement in Brazil with Sansão Holding S.A. and with Toxicologia Pardini Ltda., our existing independent distributor in Brazil, forme

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 19, 2019 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission F

PMD / Psychemedics Corp. S-8 - - S-8

Registration No. ] Securities and Exchange Commission Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PSYCHEMEDICS CORPORATION (Exact name of issuer as specified in its charter) DELAWARE 58-1701987 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 289 Great Road, Acton, Massachusetts 01720 (Address of princip

2006 Incentive Plan, as amended and restated on January 24, 2019 and ratified by the stockholders of the registrant on May 3, 2019

Exhibit 4.2 PSYCHEMEDICS CORPORATION 2006 INCENTIVE PLAN As Amended and Restated on January 24, 2019 and Ratified by the Stockholders on May 3, 2019 1. Establishment, Purpose; Duration; Definitions A. Establishment of the Plan. This 2006 Incentive Plan (the “Plan”) was first adopted by the Board of directors of Psychemedics Corporation, a Delaware corporation (hereinafter referred to as the “Compa

Power of Attorney

Exhibit 24.1 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned, being a director, officer or both, of PSYCHEMEDICS CORPORATION, a Delaware corporation (hereinafter the “Corporation”), does hereby constitute and appoint, RAYMOND C. KUBACKI and PATRICK J. KINNEY, JR., with full power to each of them to act alone, as the true and lawful attorneys and agents of the undersi

PMD / Psychemedics Corp. 10-Q - Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 or [ ] Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS CORP

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 23, 2019 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission File N

Psychemedics Announces Second Quarter Results and Declares 92nd Consecutive Quarterly Dividend

EXHIBIT 99.1 Psychemedics Announces Second Quarter Results and Declares 92nd Consecutive Quarterly Dividend ACTON, Mass., July 23, 2019 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2019. The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of August 6, 2019,

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2019 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R.S. E

PMD / Psychemedics Corp. 10-Q (Quarterly Report) FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 or [ x] Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS CO

Psychemedics Announces First Quarter Results and Declares 91st Consecutive Quarterly Dividend

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Psychemedics Announces First Quarter Results and Declares 91st Consecutive Quarterly Dividend ACTON, Mass., April 23, 2019 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD) today announced first quarter financial results for the period ended March 31, 2019. The Company also announced a quarterly dividend of $0.18 per share payable to sharehold

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 23, 2019 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission File

PMD / Psychemedics Corp. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

PMD / Psychemedics Corp. FORM DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

PMD / Psychemedics Corp. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 4, 2019 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission File N

Psychemedics Corporation Announces 3rd Straight Year of Record Revenue; Declares 90th Consecutive Quarterly Dividend

EXHIBIT 99.1 Psychemedics Corporation Announces 3rd Straight Year of Record Revenue; Declares 90th Consecutive Quarterly Dividend ACTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2018. The Company also announced a quarterly dividend of $0.18 per share payable to shar

Power of Attorney

EX-24 9 exh24.htm EXHIBIT 24 EXHIBIT 24 Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned, being a director or officer, or both, of Psychemedics Corporation, a Delaware corporation (hereinafter called the “Corporation”), does hereby constitute and appoint Raymond C. Kubacki and Neil L. Lerner, with full power to each of them to act alone, as the true and lawful attorne

Subsidiaries of the Registrant

EXHIBIT 21.1 PSYCHEMEDICS CORPORATION Subsidiaries Psychemedics Corporation wholly-owns the following companies: Name Country of Incorporation 1. Psychemedics International, LLC Delaware, USA 2. Psychemedics Laboratórios Ltda Brazil (owned jointly by Psychemedics Corporation and Psychemedics International, LLC)

PMD / Psychemedics Corp. FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-13738 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified

Change in control severance agreement with Ray Kubacki dated February 20, 2018 — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019)

EX-10.9 2 exh109.htm EXHIBIT 10.9 Exhibit 10.9 February 20, 2018 CONFIDENTIAL Mr. Raymond C. Kubacki c/o Psychemedics Corporation 125 Nagog Park Suite 200 Acton, MA 01720 Dear Ray: This letter sets forth the agreements we have made regarding your employment with Psychemedics Corporation (the “Company”). Definitions not defined in the text below shall have the meanings set forth in Paragraph 14. 1.

Change in control severance agreement with Charles Doucot dated May 1, 2018 — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019)

EX-10.11 4 exh1011.htm EXHIBIT 10.11 Exhibit 10.11 May 2, 2018 CONFIDENTIAL Charles Doucot c/o Psychemedics Corporation 289 Great Road Acton, MA 01720 Dear Charlie: This letter sets forth the agreements we have made regarding your employment with Psychemedics Corporation (the “Company”). Definitions not defined in the text below shall have the meanings set forth in Paragraph 14. 1. If at any time

Change in control severance agreement with Michael Schaffer dated February 20, 2018 — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019)

Exhibit 10.10 February 20, 2018 CONFIDENTIAL Michael I. Schaffer, Ph.D. c/o Psychemedics Corporation 5832 Uplander Way Culver City, CA 90230-6608 Dear Mike: This letter sets forth the agreements we have made regarding your employment with Psychemedics Corporation (the “Company”). Definitions not defined in the text below shall have the meanings set forth in Paragraph 14. 1. If at any time after th

Severance agreement with Charles Doucot dated February 26, 2019 — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019)

Exhibit 10.12 February 26, 2019 CONFIDENTIAL Charles Doucot c/o Psychemedics Corporation 289 Great Road Acton, MA 01720 Dear Charlie: This letter sets forth the agreements we have made regarding your employment with Psychemedics Corporation (the “Company”). Definitions not defined in the text below shall have the meanings set forth in Paragraph 10. 1. If at any time after the effective date hereof

Second Amendment to Lease dated March 12, 2014 with Bristol-Culver Associates, LLC and Mountain Organic Farms, LLC with respect to 6100 Bristol parkway premises in Culver City, CA

EX-10.13.1 6 exh10131.htm EXHIBIT 10.13.1 Exhibit 10.13.1 DocuSign Envelope ID: 76DDFD05 - C690 - 479E - 9696 - BAEA10803213 DocuSign Envelope ID: 76DDFD05 - C690 - 479E - 9696 - BAEA10803213 DocuSign Envelope ID: 76DDFD05 - C690 - 479E - 9696 - BAEA10803213 1/2/2019

PMD / Psychemedics Corp. / CRAWFORD INVESTMENT COUNSEL INC Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* Psychemedics Corporation (Name of Issuer) Common stock, $0.005 par value (Title of Class of Securities) 744375205 (CUSIP Number) December 31, 2018 (Date

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2019 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 1-13738 58-1701987 (State or Other Jurisdiction (Commission File Number) (I.R

PMD / Psychemedics Corp. / DEPRINCE RACE & ZOLLO INC - SCHEDULE 13G HOLDINGS REPORT Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

PMD / Psychemedics Corp. FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 or [ ] Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-13738 PSYCHEMEDICS

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 23, 2018 PSYCHEMEDICS CORPORATION (Exact Name of Registrant as Specified in Charter) Deleware 1-13738 58-1701987 (State or Other Jurisdiction of Incorporation) (Commission Fil

Psychemedics Announces Quarterly Results Declares 89th Consecutive Quarterly Dividend

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Psychemedics Announces Quarterly Results Declares 89th Consecutive Quarterly Dividend ACTON, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) - Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2018. The Company also announced a quarterly dividend of $0.18 per share payable to shareholders o